Vitamin D Deficiency in Coronary Artery Disease

Status Completed

Clinical Trial Summary

Large population cross sectional study, was conducted between 2018-2020 by attendance of 4526 patients in shiraz, Iran. Patients were undergone selective coronary angiography from radial artery approach by an expert interventional cardiologist. 25-hydroxy vitamin D and Hs-CRP levels were measured for all patients

Clinical Trial Description

This cross-sectional study was conducted in Shiraz. Clinical data were collected from the patients of Professor Kojuri cardiovascular clinic in Shiraz, Iran ( Iran, Fars Province, Shiraz, Niayesh Boulevard, Email: kojurij@yahoo.com, webpage: http://kojuriclinic.com/ )who came to clinic from March 2018 to March 2020. Inclusion criteria was all of the new patients who referred to Professor Kojuri cardiovascular clinic. Exclusion criteria were patients with more than 100ng/ml 25-hydroxy vitamin D3 serum level, parathyroid disorders, end-stage-renal-disease (ESRD) and paraneoplastic syndromes. Patients with more than 10mg/L Hs-CRP serum level also were excluded. Complete history and physical exam were taken from the patients and risk factors such as hypertension, diabetes mellitus, age and gender were considered. 25-hydroxy vitamin D3 was checked for all patients. Blood pressure and took electrocardiography (ECG) for all patients were done. The dependent variable was the prevalence of Coronary Artery disease; the independent variable was vitamin D deficiency; and intervening factors were age, gender, hypertension, diabetes mellitus and level of Hs-CRP. All Patients were undergone selective coronary angiography from radial artery approach by an expert interventional cardiologist. Angiography videos were reviewed by a team of expert cardiologists. Based on the results of coronary angiography, patients were classified as non-significant CAD with stenosis less than 50% and significant CAD with stenosis more than 50% stenosis. In this review diabetic and hypertensive patients is considered by criteria of American diabetes association 2018 & American heart association 2017 . Patient's serum level of 25-hydroxy vitamin D on their first visit was considered as index of vitamin D level. Vitamin D deficiency and sufficiency are defined respectively as serum level of 25-hydroxy vitamin D less than 30ng/ml and serum level of 25-hydroxy vitamin D more than 30 ng/ml . Patients with Parathyroid disorders and paraneoplastic syndromes were excluded ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04651101
Study type	Observational
Source	Shiraz University of Medical Sciences
Contact
Status	Completed
Phase
Start date	March 1, 2019
Completion date	November 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Completed	`NCT05672862` - International Post-PCI FFR Extended Registry
Completed	`NCT04492423` - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed	`NCT00046410` - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Completed	`NCT02948517` - Time Restricted Feeding for Weight Loss and Cardio-protection	N/A
Completed	`NCT02784873` - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes	N/A
Not yet recruiting	`NCT02895009` - Hemostatic Compression Patterns After Transradial Coronary Intervention	N/A
Recruiting	`NCT02859480` - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI	Phase 4
Withdrawn	`NCT02418143` - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Completed	`NCT02382731` - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction	N/A
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Recruiting	`NCT01681381` - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization	N/A
Completed	`NCT02248415` - Administration of Warm Blood Cardioplegia With or Without Roller Pump	N/A
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Completed	`NCT02088138` - Functional Electrical Stimulation in Cardiac Patients	N/A
Completed	`NCT02173067` - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective	N/A
Completed	`NCT02133807` - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.